We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
+10.66%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$239M
AUM Growth
+$41.4M
(+21%)
Cap. Flow
+$18M
Cap. Flow
% of AUM
7.51%
Top 10 Holdings %
Top 10 Hldgs %
39.46%
Holding
44
New
11
Increased
12
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$6.14M |
| 2 |
Abbott
ABT
|
+$5.25M |
| 3 |
Smith & Nephew
SNN
|
+$4.71M |
| 4 |
Inspire Medical Systems
INSP
|
+$4.46M |
| 5 |
DaVita
DVA
|
+$4.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$4.72M |
| 2 |
Avantor
AVTR
|
+$3.79M |
| 3 |
CTLT
CATALENT, INC.
CTLT
|
+$3.64M |
| 4 |
IQVIA
IQV
|
+$3.44M |
| 5 |
Cencora
COR
|
+$2.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
UnitedHealth
UNH
$364B
| $5.26M | 2.2% |
10,000
-5,000
| -33% | -$2.67M |
|
27
Cigna
CI
$73.3B
| $5.24M | 2.19% |
17,500
-7,500
| -30% | -$2.19M |
|
|
28
Smith & Nephew
SNN
$12.5B
| $5.18M | 2.17% |
+190,000
| New | +$4.71M |
|
29
Vertex Pharmaceuticals
VRTX
$133B
| $5.09M | 2.12% |
12,500
+40
| +0.3% | +$14.8K |
|
|
30
DaVita
DVA
$11.6B
| $4.71M | 1.97% |
+45,000
| New | +$4.16M |
|
31
Quest Diagnostics
DGX
$26.3B
| $4.14M | 1.73% |
+30,000
| New | +$3.94M |
|
|
32
Cencora
COR
$59.9B
| $4.11M | 1.72% |
20,000
-15,000
| -43% | -$2.93M |
|
33
Cardinal Health
CAH
$54.5B
| $4.03M | 1.68% |
40,000
-20,000
| -33% | -$1.98M |
|
34
ResMed
RMD
$32.8B
| $3.44M | 1.44% |
+20,000
| New | +$3.07M |
|
35
Labcorp
LH
$26.2B
| $3.41M | 1.42% |
+15,000
| New | +$3.15M |
|
36
Qiagen
QGEN
$8.88B
| $2.39M | 1% |
+51,868
| New | +$2.21M |
|
|
WBA
37
DELISTED
Walgreens Boots Alliance
WBA
| $2.35M | 0.98% |
+90,000
| New | +$2.01M |
|
38
Stevanato
STVN
$5.8B
| $2.18M | 0.91% |
80,000
+3,928
| +5% | +$113K |
|
39
Maravai LifeSciences
MRVI
$863M
| $1.34M | 0.56% |
+205,241
| New | +$1.33M |
|
|
40
Avantor
AVTR
$9.43B
| – | – |
-180,000
| Closed | -$3.79M |
|
|
41
Baxter International
BAX
$13.9B
| – | – |
-125,000
| Closed | -$4.72M |
|
42
Icon
ICLR
$12.9B
| – | – |
-10,000
| Closed | -$2.46M |
|
|
43
IQVIA
IQV
$39.8B
| – | – |
-17,500
| Closed | -$3.44M |
|
|
CTLT
44
DELISTED
CATALENT, INC.
CTLT
| – | – |
-80,000
| Closed | -$3.64M |
|
Similar funds
AFP
PCGDR
ACM
9C
STFP
ADEF
AC
CIP
Sivik Global Healthcare's Q4 2023 Portfolio in Review
As of Q4 2023, Sivik Global Healthcare held 44 positions worth $239M, up 21% from $198M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Sivik Global Healthcare deployed $18M of net new capital in Q4 2023, opening 11 new positions and adding to 12 existing holdings. Its largest new stake was Biogen: 25,000 shares worth $6.47M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier.
On the sell side, the largest reduction was Cencora, an estimated $2.93M trimmed.
- Sivik Global Healthcare's largest Q4 2023 buy was Biogen: 25,000 shares worth $6.47M.
- Sivik Global Healthcare added most to State Street SPDR S&P Biotech ETF in Q4 2023, an estimated $2.64M increase.
- Sivik Global Healthcare's biggest Q4 2023 reduction was Cencora, cutting an estimated $2.93M.
- Sivik Global Healthcare fully exited Baxter International in Q4 2023, selling an estimated $4.72M.
- Sivik Global Healthcare's ten largest holdings make up 39% of its $239M portfolio in Q4 2023.
- Sivik Global Healthcare opened 11 new positions and closed 5 in Q4 2023.
- Sivik Global Healthcare's portfolio value rose 21% quarter-over-quarter to $239M.
Based on Sivik Global Healthcare's 13F filing for Q4 2023, filed 5 Feb 2024.